Ashland Inc. (ASH)
| Previous close | 97.56 |
| Open | 97.74 |
| Bid | 97.70 x 800 |
| Ask | 97.84 x 800 |
| Day's range | 96.76 - 98.37 |
| 52-week range | 70.82 - 99.55 |
| Volume | |
| Avg. volume | 340,706 |
| Market cap | 4.91B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 27.06 |
| EPS (TTM) | 3.62 |
| Earnings date | 23 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 1.62 (1.66%) |
| Ex-dividend date | 31 May 2024 |
| 1y target est | 111.50 |
ZacksAshland (ASH) to Divest Nutraceuticals Business to Turnspire
Ashland (ASH) is set to sell its nutraceuticals business to Turnspire Capital Partners, with the deal expected to close in third-quarter 2024.
GlobeNewswireAshland Board appoints Ashish K. Kulkarni as new director
WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corpo
ZacksAshland (ASH) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
